With the European Union (EU) set to begin its next 5-year mandate in 2019, the debate around public health remains lively across the continent. European citizens expect high levels of healthcare, including the provision of new, innovative medicines. Meanwhile, policy-makers must continuously explore ways in which to make health systems more sustainable and equitable, while faced with growing demographic and political challenges.
In this context, Lilly carried out a survey of the general public in six European countries (Belgium, France, Germany, Ireland, Italy and Spain) to gauge views on a series of health-related topics, such as public awareness of the scale and scope of research and development (R&D) in the biopharmaceutical industry, access to medicines, digital health, and healthcare priorities.
All aggregated and country findings may be found in the report.